Oncolytics Biotech INC 8-K filings

Oncolytics Biotech Inc. received a notification from Nasdaq for failing to meet the minimum $1.00 bid price requirement, with 180 days to regain compliance.

Oncolytics Biotech's pelareorep in combination with a checkpoint inhibitor has received FDA Fast Track designation for advanced anal cancer, targeting a significant unmet need.

Oncolytics Biotech announces FDA Type D meeting to discuss registrational pathway for REO 033 study in RAS-mutant colorectal cancer, with Part B designed for accelerated approval.

Oncolytics Biotech Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm, replacing Ernst & Young LLP due to corporate restructuring.

Oncolytics Biotech announced a new U.S. patent protecting its pelareorep manufacturing process until 2044, bolstering its intellectual property portfolio.

Oncolytics Biotech Inc. announced the appointment of John McAdory as Chief Operating Officer and Stephen Glover as a new Director to its Board.

Oncolytics Biotech announced positive initial preclinical data for pelareorep in combination with RAS inhibitor modalities, supporting further studies in pancreatic and colorectal cancer.

Oncolytics Biotech announced new translational data from its GOBLET and AWARE-1 studies demonstrating pelareorep's immune-activating mechanism in gastrointestinal cancers.

Oncolytics Biotech announces significant durability data from its REO 022 study in metastatic colorectal cancer, showing a substantial improvement in duration of response for patients with RAS-mutant MSS disease.

Oncolytics Biotech has reached an agreement with the FDA on the design for a pivotal clinical study of pelareorep in metastatic squamous cell carcinoma of the anal canal.

Oncolytics Biotech Inc. has entered into an Open Market Sale Agreement with Jefferies LLC to offer and sell up to $75 million of its common stock.

Oncolytics Biotech has scheduled an April 16, 2026, Type C meeting with the FDA to discuss a single-arm registrational study for pelareorep in squamous cell anal carcinoma.

Oncolytics Biotech Inc. has completed its redomestication from Canada to Nevada, aiming for greater operational efficiency and improved access to U.S. capital markets.

Oncolytics Biotech Inc. has completed the first phase of its redomestication, moving its incorporation from Alberta to British Columbia, with a further move to Nevada planned for March 31, 2026.

Oncolytics Biotech announced two abstracts on pelareorep's immune-priming capabilities in pancreatic and breast cancer were accepted for presentation at the AACR Annual Meeting 2026.

Oncolytics Biotech Inc. announced the initiation of a randomized Phase 2 study, REO 033, for metastatic colorectal cancer patients, building on previous compelling efficacy data and a recent Fast Track Designation.

Oncolytics Biotech shifts focus to registrational studies in anal and colorectal cancer, concluding GOBLET enrollment with sufficient cash.

Oncolytics Biotech Inc. received FDA Fast Track Designation for pelareorep in combination therapy for second-line KRAS-mutant MSS metastatic colorectal cancer, showing strong efficacy signals.

Oncolytics Biotech Inc. shareholders approved resolutions to move the company's domicile from Alberta to British Columbia, then to Nevada, and to adopt a new incentive award plan.

Oncolytics Biotech strengthens its executive team with key appointments to drive late-stage clinical development and operational strategy for its pelareorep programs.

Oncolytics Biotech announced significant updates on its intellectual property strategy for pelareorep and positive clinical data from its GOBLET Cohort 4 study in third-line anal cancer.